June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Improvement of Key Clinical Parameters of Dry Eye Disease after 12 Months Treatment with Cyclosporine 0.05% Eye Drops
Author Affiliations & Notes
  • Tor Paaske Utheim
    Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
  • Xianjun Chen
    The Norwegian Dry Eye Clinic, Oslo, Norway
  • Sten Raeder
    The Norwegian Dry Eye Clinic, Oslo, Norway
  • Øygunn Utheim
    Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
  • Aleksandar Stojanovic
    The Norwegian Dry Eye Clinic, Oslo, Norway
  • Darlene A Dartt
    Department of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Behzod Tashbayev
    The Norwegian Dry Eye Clinic, Oslo, Norway
  • Footnotes
    Commercial Relationships   Tor Utheim, None; Xianjun Chen, None; Sten Raeder, None; Øygunn Utheim, None; Aleksandar Stojanovic, None; Darlene Dartt, None; Behzod Tashbayev, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2660. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tor Paaske Utheim, Xianjun Chen, Sten Raeder, Øygunn Utheim, Aleksandar Stojanovic, Darlene A Dartt, Behzod Tashbayev; Improvement of Key Clinical Parameters of Dry Eye Disease after 12 Months Treatment with Cyclosporine 0.05% Eye Drops. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2660.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate one-year follow-up changes in clinical parameters of dry eye disease (DED) in patients receiving cyclosporine 0.05% eye drops (Restasis, Allergan) in a Norwegian cohort of dry eye patients.

Methods : Three hundred forty patients (79% female/21% male, age 54.8±15.8 years) with DED of mixed etiologies presenting with signs of inflammation, for whom Restasis eye drop treatment was prescribed from their first visit at the Norwegian dry eye clinic, were consecutively included in the study. The patients underwent comprehensive dry eye work-up at baseline and after 12 months. The work-up included assessment of tear film break-up time (TFBUT), ocular surface staining using the Oxford grading scheme, Schirmer test I, meibum expressibility (ME), meibum quality (MQ) and dry eye severity level (DESL). Besides Restasis eye drops, all patients received additional preservative-free tear substitutes during 12 months. Wilcoxon signed rank test was used for statistical analyses. Results are presented as mean and standard deviation.

Results : TFBUT increased from 3.67±3.04 at baseline to 6.92±5.536 after 12 months (p<0.001). Vital staining decreased from 2.77±2.483 to 1.37±1.715 (p<0.0001). A decrease in ME was observed (1.39±0.976 at baseline compared to 1.07±1.0 after 12 months, p=0.019). DESL decreased from 2.21±0.547 at baseline to 1.81±0.485 at one year follow-up (p<0.0001). Changes in results of Schirmer I test and MQ were not significant.

Conclusions : Topical cyclosporine treatment for DED proved effective with improvement of key clinical parameters of DED at 12 months follow-up.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×